Article By: Zachy Hennessey, Israel21C
Date Published: February 12, 2025
Israel is investing 113 million shekels (about $35.5 million) in its first laboratory dedicated to bio-devices and biochips.
The December announcement by the Israel Innovation Authority (IIA) marks a significant step into the growing field of bio-convergence, underlining the country’s intention of becoming a global leader in this relatively new approach to healthcare and scientific research.
What exactly is bio-convergence, and why does it matter?
Bio-convergence brings together experts from different fields of study to create novel solutions to a wide variety of needs: in medicine, environment, energy, agriculture, food, security and more.
MeMed Diagnostics Co-founder and CTO Kfir Oved and Israel Innovation Authority CEO Dror Bin are both Technion alumni.
Click here to continue reading the full article in Israel21C
